Vir Biotechnology, Inc. — Form 8-K
Filed October 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Vir Biotechnology announced the appointment of Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026. Sawaf brings 20+ years of biopharmaceutical experience, most recently as CFO of Theravance Biopharma since 2023, and previously held financial leadership roles at Gilead Sciences. He will lead finance, IT, and investor relations functions.
Why this rating
Standard C-suite succession; no compensation, severance, or predecessor transition details disclosed; typical executive appointment for clinical-stage biotech.
See more from October 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.